Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.

Christian Grohé,T Wehler,Tobias Dechow,Sven Henschke,Wolfgang Schuette,Ina Dittrich,Stefan Hammerschmidt,H. Müller-Huesmann,Christian Schumann,Stefan Krüger,Judith Atz,Rolf Kaiser

Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.

2021

Christian Grohé
T Wehler
Tobias Dechow
Sven Henschke
Wolfgang Schuette
Ina Dittrich
Stefan Hammerschmidt
H. Müller-Huesmann
Christian Schumann
Stefan Krüger
Judith Atz
Rolf Kaiser

9033Background: The treatment landscape in advanced non-small cell lung cancer (NSCLC) has undergone significant changes, with immune checkpoint inhibitor (ICI) +/- chemotherapy now the preferred f...

Keywords:

Internal medicine
Docetaxel
Adenocarcinoma
Combination therapy
Medicine
Lung
Chemotherapy
Cohort
Oncology
Nintedanib
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations